News | August 19, 2024
Aptar’s nasal unidose system delivers FDA-approved neffy
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
Becomes the first rehab & recovery center in east India to earn NABH accreditation
India Business grew by 11.9% YoY to Rs. 1196.2 crore
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Subscribe To Our Newsletter & Stay Updated
